All In MedTech

Device Trial Radar · NCT07277296

CGUARDIANS III IDE Pivotal Trial

A Multicenter, Single-arm, Pivotal Study to Evaluate the Safety and Efficacy of the SwitchGuard™ Neuroprotection System (NPS) for Providing Cerebral Embolic Protection During Carotid Artery Stenting Via the Transcarotid Artery Revascularization (TCAR) Approach When Used in Conjunction With the CGuard™ Prime 80 Carotid Stent System

Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

103

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Feb 1, 2027

Study completion Feb 1, 2028

Sponsor

Lead sponsor
InspireMDNot on our public-company list
Sponsor type
Industry
First posted
Dec 11, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 82 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, single-arm, pivotal study. The objective of this study is to evaluate the safety and efficacy of the SwitchGuard NPS in providing cerebral embolic protection during Transcarotid Artery Revascularization procedures using the CGuard Prime Carotid Stent System 80 in the treatment of carotid artery stenosis in patients at high risk for complications from CEA.

Conditions

  • Carotid Artery Stenosis

Interventions

  • SwitchGuardTM NPSDevice

    The CGuard Prime™ 80 will be used in conjunction with the SwitchGuard™ NPS for the carotid artery stenting implantation procedure that will be performed by physician investigators experienced with transcarotid artery revascularization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite primary endpointTime frame: 30 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.